Brind.

The FDA has issued guidance outlining the clinical trial requirements for new drug classes, including psychedelic drugs.

Steady: 0 in the last 7 days Updated oct 16

The latest in this situation

  1. Cleveland Clinic and Harvard Medical School provided input on psychedelic drug regulation.

How it started

1 report, 1 independent, last reported Jul 29. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA has issued guidance outlining the clinical trial requirements for new drug classes, including psychedelic drugs.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Cleveland Clinic and Harvard Medical School provided input on psychedelic drug regulation.Sub-event
  2. Richard Langford provided expert comments on psychedelic drug access and is receiving feedback on clinical psychedelic programs.Sub-event
  3. FDA guidance outlines clinical trial requirements for new drug classes.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped